Epothilones are a new class of natural products that bind to tubulin and prevent the depolymerization of microtubules, although they have no structural similarity to paclitaxel. Taxanes are only marginally effective in the treatment of disseminated prostate cancer, although they may have useful activity when administered in combination with estramustine. Unlike paclitaxel, epothilones are not substrates for P-glycoprotein and are active in multidrug resistant cells. Epothilones A and B (EA, EB) have recently been synthesized in toto. In this report, we examine the effects of synthetic epothilones and their desoxy derivatives, as well as paclitaxel, on prostate cancer cell lines. EB was the most active of these compounds in tissue culture (IC 50 : 50 ± 75 pM), four to ten-fold more potent than paclitaxel. EA and the desoxyderivatives of EA and EB (dEA, dEB) were also active, but less potent than EB. Each of these compounds causes mitotic block followed by apoptotic cell death. The relative potencies for cell cycle arrest and cytotoxicity directly correlate with the ability of the drugs to bind microtubules, stabilize mitotic spindles and induce the formation of interphase microtubule bundles. Therefore, synthetic epothilones are potent inhibitors of prostate cancer cell lines and work in a fashion similar to paclitaxel. Recently, we showed that farnesyl transferase inhibitors sensitize tumor cells to paclitaxelinduced mitotic arrest. We now have extended these observations to show that paclitaxel and the epothilones synergize with FTI to arrest the growth of prostate cancer cells. Moreover, this occurs in DU145, a cell line that is not particularly sensitive to the FTI. The combination of FTI and epothilone represent a new potential clinical strategy for the treatment of advanced prostatic cancer.
Introduction
Metastatic prostate cancer is dif®cult to treat and is relatively refractory to chemotherapeutic agents. 1, 2 Progress in the treatment of this disease could well bene®t from development of new agents. 3 Epothilones are 16-membered macrolides isolated from the myxobacterium Sorangium cellulosum. 4, 5 These compounds were originally described as antifungal agents, however, their use was limited because of an associated herbicidal activity. The tumor cytotoxicity of these drugs was revealed when they were tested in the NCI 60-cell line screen. Epothilones inhibited the growth of a variety of human tumor cell lines with an IC 50 in the 100 pM range. 4, 6, 7 The mechanism whereby epothilones exert their cellular effects is similar to that of paclitaxel. 6, 7 Epothilones bind to tubulin and cause the hyperstabilization of microtubules with subsequent mitotic arrest and apoptotic cell death. 6, 7 Both epothilones and taxanes bind a,b-tubulin heterodimers in a 1:1 stoichiometric ratio and epothilones are capable of displacing bound, labeled paclitaxel at concentrations, and with kinetics similar to those displayed by paclitaxel itself. 6 ± 8 Despite these mechanistic similarities, the structures of the two drugs are quite different and no obvious and convincing homology modeling has yet established a common pharmacophore ( Figure 1 ). Furthermore, whereas taxanes are substrates for P-glycoprotein, epothilones are not. Cells with the mdr phenotype that are resistant to taxanes remain sensitive to epothilones. 6 ± 10 This ability of the epothilones to outperform paclitaxel in mdr contexts constitutes a potentially important advantage for this family of agents relative to the taxanes. Furthermore the epothilones may provide advantages relative to paclitaxel in terms of the ease of formulatability. 5 Moreover, paclitaxel is not considered to be an effective agent for prostate cancer, although it has recently been shown to have activity when administered with estramustine.
11 ± 15 The reasons that prostate cancers are resistant to paclitaxel are unknown, although the high levels of P-glycoprotein and Bcl-2 expression observed in advanced tumors may play a role. 2, 16 Recently, the total synthesis of epothilones A and B (EA, EB) and their desoxy counterparts (dEA, dEB) was accomplished in these laboratories 10, 17 and others. 18 ± 20 We now report potent in vitro cytotoxicity effects of these synthetically derived epothilones on prostate cancer cells. Each epothilone caused stabilization of microtubules that caused cells to become growth arrested in mitosis and undergo programmed cell death, EB was the most active agent. Epothilones had synergistic activity when given in combination with a farnesyl:protein transferase inhibitor, even in prostate cells that are relatively insensitive to both drugs. We conclude that epothilones, a class of compounds that stabilize microtubules and are P-glycoprotein independent, are active against prostate cancer cell lines and may comprise a new treatment modality for this disease.
Materials and methods

Materials
Epothilones A and B and their desoxy counterparts were synthesized according to References 10 and 17. Stock solutions were prepared in dimethylsulfoxide (DMSO), fractionated and stored at 780 C. One-thousand-fold concentrated working solutions were similarly prepared and stored. The farnesyl:protein transferase inhibitor (FTI) L-744,832 was from Merck & Co. (West Point, PA). FTI was dissolved in PBS and stored 780 C.
Cell lines
The human prostate carcinoma cell lines, DU145 and TSU-Pr1, were obtained from the American Type Culture Collection and from Dr D Nanus (Genitourinary Service, MSKCC), respectively. Both cell lines were grown in DME:F12 (1:1) medium supplemented with 10% FBS, 2 mM glutamine and 50 units/ml each of streptomycin and penicillin. Cultures were grown at 37 C in 10 cm dishes in a humidi®ed incubator with 5% CO 2 /air.
Immuno¯uorescence
The effects of epothilones on the microtubule network were studied in cell cultures treated with dimethylsulfoxide (DMSO) or epothilones for 24 h. Cells¯oating in the media were collected by centrifugation and attached cells were trypsinized. These populations were combined and cell number was determined with a Coulter counter. Aliquots of 10 6 cells were washed with phosphate-buffered saline (PBS) and ®xed with 100% methanol for 10 min at 720 C. Alternatively, cells were grown and treated on ®bronectin-coated slides placed in multiwell plates. Fixed cells were rehydrated in PBS for 10 min at room temperature and exposed for 30 min at 37 C to a blocking solution consisting of 2% bovine serum albumin (BSA), 10% normal goat serum and 0.05% Tween-20 in PBS. Tubulin was detected by immunostaining with a monoclonal anti-tubulin-a antibody (clone 5B-152 from Sigma.) Cells and slides were incubated with a 1:1000 dilution of the primary antibody in blocking buffer for 1 h at room temperature, followed by an incubation with uorescein isothiocyanate (FITC)-coupled anti-mouse IgG goat secondary antibodies (Molecular Probes) (1:100 dilution in blocking buffer). Cells were washed three times with 1 ml of 0.5% BSA in 0.05% Tween-20 in PBS between and after incubations with primary and secondary antibodies. DNA was stained with bisbenzimide, which was included in the secondary antibody solution (3 mg/ml ®nal concentration). Cells grown on coverslips were mounted on glass slides with Vectashield (Vector), to prevent quenching of¯uorescence. For cells stained in suspension, a 1:1 mixture of the cell suspension with Vectashield was prepared. After equilibrating the mixture at room temperature for 5 min, 7 ml were placed under a 22 622 mm coverslip. Immuno¯uorescence was detected with a Zeiss epi¯uorescence microscope, at 40Â and 100Â, using appropriate ®lters for detection of FITC and bisbenzimide. Each ®eld was photographed using both ®lters, slides were also analyzed via confocal microscopy.
Cell cycle analysis and determination of apoptosis
Nuclear and whole cell samples were prepared for cell cycle analysis according to References 21 and 22. Ethidium iodide-stained nuclei and propidium iodide-labeled cells were analyzed with a Becton Dickinson¯uorescence-activated cell sorter (FACS). Ungated data was employed to calculate the percentage of cells containing less than 2n DNA content, which connotes the presence of apoptotic cells. Apoptosis was con®rmed by morphological evaluation of the samples via quantitative¯uorescence microscopy. For this purpose, 10 5 cells were ®xed in 3% paraformaldehyde in PBS and stored at 4 C until further analysis. Cells were then washed with PBS and resuspended in 25 ml of PBS containing 3 mg/ml of bisbenzimide. Over 400 cells were counted on duplicate slides to obtain a statistically relevant number, and the experiment was repeated at least twice.
Cell proliferation assay
To investigate the effect of epothilones on the proliferation of human tumor cell lines, 6-well plates were seeded at 10 000 cells per well and treated for 4 h with increasing epothilone concentrations. Control cultures were exposed to 0.1% DMSO. Cultures were then washed twice with PBS and grown for 5 ± 7 d, depending on the density of vehicle-treated controls. In experiments in which epothilones were combined with the farnesylation inhibitor, cells were treated with the epothilone for 4 h then the FTI was added for the length of the experiment. Cell number was determined with a Coulter counter following trypsinization of the monolayers. Each condition was 
Results
Effect of epothilones on anchorage-dependent growth of human prostate cancer cell lines
We determined the effects of synthetic epothilones and desoxyepothilones (Figure 1 ) on the growth of TSU-Pr1 and DU145 human prostate cancer cells. Continuous treatment with these drugs had a profound antiproliferative effect ( Figure 2 and Table 1 ). EB was the most active epothilone, approximately 7-to 10-fold more active than paclitaxel in inhibiting the anchorage-dependent growth of human prostate cancer cells (0.05 ± 0.06 nM for EB vs 0.22 ± 0.6 nM for Paclitaxel) ( Figure 2 and Table 1 ). Among the epothilones, the order of potency was EB, followed by dEB, EA and dEA, which were 5-, 23-and 360-fold less potent, respectively, than the parent EB ( Figure 2 and Table 1 ).
Microtubule stabilization and induction of apoptosis
Microscopic examination of the cultures treated with epothilones revealed an increase in the number of detached cells and an increase in cellular debris. The cells that remained attached exhibited clear cytoskeletal changes. As shown in the confocal micrographs of TSUPr1 cells stained for tubulin (green) and DNA (blue) (Figure 3 ), increasing concentrations of EB resulted in 
Effect of epothilones on cell cycle dynamics of human prostate cancer cell lines
We conducted¯ow cytometric analysis to investigate the effects of these drugs on cell cycle progression and cell death. A 24 h treatment with epothilones induced a dosedependent increase in the proportion of cells with less than a diploid DNA content. A representative ungated FACS analysis pro®le for TSU-Pr1 cells treated with or without 10 nM EB for 24 h is shown in Figure 5 . The appearance of a`sub-G1' population correlates with the DNA fragmentation that occurs during cell death by apoptosis. As described below, the epothilones induced programmed cell death of human prostate cancer cells. Figure 5 shows a graphic representation of the changes in the sub-G1 population induced by epothilones and paclitaxel. The relative potencies for DNA cleavage correlate with the IC 50 s obtained for inhibition of cell growth. FACS analysis was also employed to investigate changes in cell cycle distribution. As shown for Figure  6 , epothilones induced a dose-dependent cell cycle arrest of cells at the G2/M stage (4n DNA content), at the expense of cells in G1. Changes in the percentages of cells in each cell cycle phase are presented in graphic form in Figure 6 . Paclitaxel and EB were the most potent in affecting the cell cycle, whereas dEB, EA and dEA were 3-to 10-fold less effective. We analyzed the distribution of cells in interphase, mitosis and apoptosis by using a combination of FACS analysis and immunostaining. As 
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shown in Figure 7 , treatment with epothilones induced mitotic arrest and death by apoptosis.
Synergistic effect of epothilones and farnesyl transferase inhibitors for growth inhibition
These data demonstrate that prostate carcinoma cells are sensitive to epothilones and that they undergo mitotic arrest and apoptosis in response to the drugs. We have recently discovered that paclitaxel synergizes with a protein farnesylation inhibitor (FTI) to inhibit the growth of human breast and prostate cancer cells. We explored the possibility that epothilones would also enhance the antiproliferative effect of the FTI. As shown in Figure 8 , pretreatment of DU145 human prostate cancer cells with epothilones sensitized the cells for a subsequent treatment with FTI. DU145 cells are particularly resistant to the FTI as a single agent (IC 50 b 20 mM), however, pretreatment with epothilones increased its effectiveness by over two orders of magnitude. An algorithm was used to calculate whether these drugs were synergistic. 23 Two drugs are considered synergistic if the surviving fraction of the combination is lower than the product of the surviving fractions for each agent alone. Based on this criterium, FTI and microtubule-stabilizing agents were synergistic in inhibiting the growth of DU145 human prostate cancer cells.
Discussion
Taxanes bind to microtubules and prevent their depolymerization. 24 This causes growth arrest of tumor cells in the mitotic and G1 phases of the cell cycle and leads to subsequent apoptosis. 25 ± 27 These compounds have potent antitumor activity and already have great utility in the treatment of several human cancers, including breast, ovarian, esophageal, lung and other tumors. 28 ± 36 However, even in cases of metastatic disease that are very sensitive to taxanes, drug resistance eventually supervenes, and many human tumors are resistant to the drug de novo.
2,34,37
These ®ndings have stimulated a search for taxane derivatives or analogs with different spectra of antitumor activities. Remarkably, recent work has shown that another class of natural products, the epothilones, bind to microtubules and exert effects on cells almost identical to those of paclitaxel. In addition, epothilones are not substrates for P-glycoprotein and are more water-soluble than taxanes.
5,7 ± 10 These properties suggest that epothilones may have different clinical uses as well. Recently, the total synthesis of epothilones A and B was accomplished in these laboratories. 10, 17 These successes allowed for the synthesis of a variety of epothilone derivatives as well. We have studied the biologic effects of EA, EB, dEA and dEB on prostate cancer cell lines and found that they all inhibit growth potently ( Figure 2 and Table 1 ). There is no indication in this system that the effects of epothilones on cells are qualitatively different from those of paclitaxel. Drug administration is associated with hyperpolymerization of microtubules, the formation of microtubular ®bers in G1, and mitotic arrest (Figures 3, 4, 6, and 7) . Cells then undergo an apoptotic cell death (Figures 5 and  7) . The drugs do vary in potency, EB is by far the most active compound with an IC 50 of 50 ± 75 pM compared to IC 50 of 200 ± 700 pM for paclitaxel. The other compounds are all active, but somewhat less potent than the parent EB (dEB, IC 50 250 pM; EA IC 50 2 nM, dEA IC 50 20 nM.) The relative potencies for mitotic arrest and cytotoxicity were What then are the potential advantages of epothilones as anticancer drugs? Firstly, they are more soluble in water than paclitaxel, perhaps leading to a much greater ease of administration. 5 Secondly, mdr cells are sensitive to epothilones. 7 ± 10 Although it is unlikely that acquired resistance to paclitaxel is mediated often by increases in Pglycoprotein expression, the mdr phenotype could play an important role in the endogenous resistance of many types of carcinoma. Thirdly, synthesis of epothilones is now possible. 10, 17, 18 This will allow the generation of multiple derivatives, some of which may have increased potency, bypass resistance mechanisms or have decreased toxicity. The similar binding and biologic effects of the very dissimilar taxane and epothilone structures suggests that synthesis of derivative drugs with altered properties will be possible.
The inadequacy of current treatments for hormoneindependent prostatic cancer is characteristic of the situation for most advanced adenocarcinomas. 1 ± 3 Paclitaxel is essentially inactive as a single agent in this disease, although it has been recently shown that the combination of paclitaxel and estramustine is effective. 11 ± 15 Both drugs bind to microtubules and cause kinetic stabilization of microtubules ,12,38,39 the molecular basis for the synergy is still unknown. It has been proposed that the two drugs use complementary mechanisms for microtubule stabilization, however, estramustine might also sensitize cells to paclitaxel by antagonizing the function of P-glycoprotein. We show in this report that prostate carcinoma cells can be quite sensitive to epothilones. The expression of Pglycoprotein has been reported to be elevated in some prostate carcinoma cell lines and in tumor tissue. If these data are con®rmed, our data suggest that epothilone may be more effective in this disease than paclitaxel. Experiments in animal models of prostate cancer are now underway to test this assertion.
We have recently shown that farnesyl transferase inhibitors inhibit the growth of tumor with wild type Ras, including prostate, breast and small cell lung carcinomas. 40 As these drugs are generally non-toxic, we went on to test whether they would be effective when given in combination with traditional cytotoxic drugs. We found that farnesyl transferase inhibitors sensitized cells to the mitotic block induced by paclitaxel and, in combination, the two drugs cause synergistic arrest of cell growth and apoptosis , 41, 42 in this report we extend these observations. Epothilones or paclitaxel in combination with farnesyl transferase inhibitors display marked synergy in inhibiting the growth of the prostate cell line DU145 (Figure 8) . Furthermore, this cell line is not particularly sensitive to either drug alone, suggesting that this combination may sensitize moderately resistant tumors. Animal experiments with these combinations are now in progress, preparatory to planning clinical trials in patients with advance prostate cancer.
Conclusions
Epothilones are natural products that bind to tubulin and prevent the depolymerization of microtubules. They have no structural similarities to taxol and they are active in Figure 8 Pretreatment with epothilones enhances the antiproliferative response of human prostate cancer cell lines to a farnesylation inhibitor (FIT). DU145 cell cultures were pretreated with drug or vehicle for 4 h prior to incubation for 5 ± 7 d in the presence or absence of increasing FTI concentrations.
Epothilones in prostate cancer cells L Sepp-Lorenzino et al multidrug resistant cells. Epothilones and various derivatives thereof have now been synthesized. In this report we compared the antitumor cell activity of these synthetic epothilones and of taxol in prostate cancer cell lines. We showed that epothilones potently inhibit the growth of metastatic human prostate carcinoma cells, several of the epothilones are more active than taxol, they cause mitotic arrest and apoptosis. Furthermore, epothilones and farnesyl transferase inhibitors have synergistic antiproliferative effects, including a cell line that is particularly refractory to the farnesylation inhibitor when given singly. Epothilones may constitute a class of drugs with taxol-like action but with a different spectrum of antitumor activity. Therefore, they may be useful in certain adenocarcinomas that are relatively resistant to taxol, such as prostate cancer.
